SCHEMBL21392046

SCHEMBL21392046

COC(=O)c1ccc(-c2cncc(C(F)(F)F)c2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.55
CYP11B2 P19099 7/20 0.55
CFTR P13569 2/20 0.47
CTPS1 P17812 2/20 0.45
PIK3CD O00329 1/20 0.43
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
BDKRB1 P46663 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
DYRK1A Q13627 2/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
WNT1 P04628 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30416001 1.00 CYP11B1 (0.55) CYP11B1CYP11B2CFTRCTPS1PIK3CD
SCHEMBL22924896 0.84 CYP11B1 (0.57) CYP11B1CYP11B2CTPS1PPARDPPARA
SCHEMBL17688761 0.84 CFTR (0.57) CFTRPPARDRXRARXRB
SCHEMBL25607364 0.83 CYP11B2 (0.55) CYP11B1CYP11B2
Potassium Ion SCHEMBL25273231 0.82 CYP11B2 (0.54) CYP11B1CYP11B2CTPS1PIK3CDPPARD
SCHEMBL21392045 0.82 CYP11B1 (0.53) CYP11B1CYP11B2CTPS1DYRK1AL3MBTL1
SCHEMBL30416332 0.82 CYP11B1 (0.53) CYP11B1CYP11B2CTPS1DYRK1AL3MBTL1
Potassium Ion SCHEMBL30416524 0.82 CYP11B2 (0.54) CYP11B1CYP11B2CTPS1PIK3CDPPARD
SCHEMBL31676635 0.78 CYP11B2 (0.48) CYP11B1CYP11B2CTPS1ALDH1A1HPGD
SCHEMBL24088755 0.78 CYP11B2 (0.48) CYP11B1CYP11B2CTPS1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717465-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
EP-3768674-B1 AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S A S (FR) 2024-01-03 EP disclosed
US-20230192673-A1 Compounds STEP PHARMA S.A.S. (FR) 2023-06-22 US disclosed
US-20230192673-A1 Compounds STEP PHARMA S.A.S. (FR) 2023-06-22 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-20210380575-A1 COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2021-12-09 US disclosed
US-20210024507-A1 Compounds STEP PHARMA S A S (FR) 2021-01-28 US disclosed
WO-2019180244-A1 AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2019-09-26 WO disclosed
WO-2019179652-A1 AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS STEP PHARMA S.A.S. (FR) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183229-A1 Compounds UGT1A1, CYP1A1, CYP1B1 CYP11B1 9/4885CYP11B2 10/4885CFTR 1204/4885
US-20210024507-A1 Compounds CYP1A1, UGT1A1, CYP1A2 CYP11B1 10/4885CYP11B2 9/4885CFTR 1143/4885
US-20210380575-A1 COMPOUNDS UGT1A1, CYP1A1, CYP1B1 CYP11B1 9/4885CYP11B2 10/4885CFTR 1204/4885
US-20230192673-A1 Compounds CYP1A1, UGT1A1, CYP1A2 CYP11B1 10/4885CYP11B2 9/4885CFTR 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.